|
시장보고서
상품코드
2077343
CKD 관련 고혈압 시장 : 약물 계열별, 유통 채널별, 지역별Hypertension in CKD Market, By Drug Class, By Distribution Channel, By Geography |
||||||
CKD(만성 콩팥병) 관련 고혈압 시장은 2026년에 3억 4,520만 달러 규모에 달할 것으로 추정되며, 2033년까지 7억 1,220만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 10.9%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 3억 4,520만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간의 CAGR: | 10.90% | 2033년 시장 규모 예측: | 7억 1,220만 달러 |
만성 콩팥병(CKD) 환자의 발병률, 사망률, 입원률 및 의료 서비스 이용률이 현저히 높습니다. 만성 콩팥병은 고혈압 등의 동반 질환으로 인해 발생할 수 있습니다. 이로 인해 환자의 혈액 속에 대사 노폐물이 축적되어 건강 이상을 일으킬 가능성이 있습니다. 만성 콩팥병의 합병증으로는 고혈압, 빈혈(혈구 수 감소), 골다공증, 영양 상태 악화, 신경 장애 등이 있습니다. 또한, 만성 콩팥병은 심근경색이나 뇌졸중 등 심장·혈관 질환이 발생할 위험을 높입니다. 이러한 문제들은 오랜 시간에 걸쳐 서서히 진행될 수 있습니다.
시장 역학
주요 기업들은 만성 콩팥병 환자를 위한 고혈압 치료법을 찾기 위해 혈압 강하제에 관한 임상시험 결과를 발표하고 있습니다. 예를 들어, 2018년에는 노바티스 인터내셔널 AG가 '엔트레스트(사쿠비트릴/발사르탄)'에 대해 긍정적인 결과를 발표했습니다. 이 회사가 실시한 임상시험에 따르면, '엔트레스트'(사큐비트릴/발살탄)은 심혈관질환을 앓고 있는 환자의 신장 기능을 유지하는 데 도움이 되는 것으로 밝혀졌습니다. 또한, '엔트레스트'(사큐비트릴/발살탄)은 안지오텐신 수용체 길항제(ARB)로 분류됩니다.
투석 치료를 받는 환자 수의 증가가 만성 콩팥병(CKD) 관련 고혈압 세계 시장의 성장을 견인할 것으로 예상됩니다. 예를 들어, 'Indian Journal of Public Health(IJPH)'에 게재된 자료에 따르면, 2018년 인도에서는 약 13만 명의 환자가 투석 치료를 받았으며, 이 수치는 2017년과 비교해 인도 인구 100만 명당 약 232명 증가한 것입니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공하고 있습니다.
- 본 조사에서는 다음의 매개변수를 바탕으로, 만성 콩팥병(CKD)에 수반되는 고혈압 분야 세계 시장에서 주요 기업들의 프로필을 작성하고 있습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 사업 전개 지역, 유통 전략, 주요 발전 사항 및 전략, 그리고 향후 계획입니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 기술 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 '만성 콩팥병(CKD) 관련 고혈압' 세계 시장 보고서는 투자자, 공급업체, 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 CKD 관련 고혈압 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 CKD 관련 고혈압 치료제 세계 시장 : 약물 계열별, 2021-030년
제5장 세계의 CKD 관련 고혈압 시장 : 유통 채널별, 2021-2033년
제6장 세계의 CKD 관련 고혈압 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.07.08Hypertension in CKD Market is estimated to be valued at USD 345.2 Mn in 2026 and is expected to reach USD 712.2 Mn by 2033, growing at a compound annual growth rate (CAGR) of 10.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 345.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.90% | 2033 Value Projection: | USD 712.2 Mn |
Persons with CKD have significantly higher rates of morbidity, mortality, hospitalizations, and healthcare utilization. Chronic kidney disease may be caused due to comorbid conditions such as high blood pressure, etc. This can lead to buildup of metabolic wastes in patient's blood and make them feel sick. Chronic kidney disease complications include high blood pressure, anemia (low blood count), weak bones, poor nutritional health, and nerve damage. Chronic kidney disease also increases the risk of developing heart and blood vessel diseases such as heart attack, stroke, etc. These problems may happen slowly over a long period of time.
Market Dynamics
Key players are involved in announcing their results for the clinical trials conducted for the antihypertensive drugs, in order to find the treatment for hypertension in patients suffering from chronic kidney disease. For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan). According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases. Moreover, Entresto (sacubitril/valsartan) belongs to angiotensin receptor blockers (ARBs) drug class.
The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market. For instance, according to the data published in the Indian Journal of Public Health (IJPH), in 2018, around 130,000 patients received dialysis treatment in India and the number increased by around 232 patients per million population in India as compared to 2017.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global hypertension in CKD market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
- Key companies covered as a part of this study include Sanofi S.A, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, AstraZeneca Plc, Novartis International AG, C.H. Boehringer Sohn AG & Ko. KG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., Ardelyx, and KBP Biosciences Holdings Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global hypertension in CKD market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the hypertension in CKD market
Detailed Segmentation:
- Global Hypertension in CKD Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
- Diuretics
- RAS Blockade
- B - Blockers
- Calcium Channel Blockers
- Others
- Global Hypertension in CKD Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Hypertension in CKD Market, By Region (Revenue, USD Mn, 2021 - 2033)
- North America
- By Drug Class:
- Diuretics
- RAS Blockade
- B - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- U.S.
- Canada
- By Drug Class:
- Latin America
- By Drug Class:
- Diuretics
- RAS Blockade
- B - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Drug Class:
- Europe
- By Drug Class:
- Diuretics
- RAS Blockade
- B - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Drug Class:
- Asia Pacific
- By Drug Class:
- Diuretics
- RAS Blockade
- B - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Drug Class:
- Middle East
- By Drug Class:
- Diuretics
- RAS Blockade
- B - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Drug Class:
- Africa
- By Drug Class:
- Diuretics
- RAS Blockade
- B - Blockers
- Calcium Channel Blockers
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Drug Class:
- Company Profiles
- Sanofi S.A*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- AstraZeneca Plc
- Novartis International AG
- H. Boehringer Sohn AG & Ko. KG
- Kissei Pharmaceutical Co., Ltd.
- Reata Pharmaceuticals, Inc.
- Ardelyx,
- KBP Biosciences Holdings Limited
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Test Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Key Developments
- Pipeline analysis
- Regulatory Scenario
- Key Developments
- Treatment Approaches
- PEST Analysis
4. Global Hypertension in CKD Market, By Drug Class, 2021 - 030, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- RAS Blockade
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- β-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
- Others (α-Blockers, Vasodilators, Proteinuria, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
5. Global Hypertension in CKD Market, By Distribution Channel, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Hypertension in CKD Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Class, 2021 -2033, (US$ Mn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 -2033, (US$ Mn)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Company Profiles
- Sanofi S.A
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- AstraZeneca Plc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- C.H. Boehringer Sohn AG & Ko. KG Kissei Pharmaceutical Co., Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- KBP Biosciences Holdings Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Ardelyx
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Reata Pharmaceuticals, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Kissei Pharmaceutical Co., Ltd
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bayer Pharmaceuticals, Inc
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GSK plc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sanofi S.A
8. Section
- References
- Research Methodology
- About us and Sales Contact
